Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)
A phase 1/2 trial of Pembrolizumab, Favezelimab, Belzutifan and Lenvatinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting.
Overview
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) is a phase 1/2 interventional study registered as NCT04626479 by Merck Sharp & Dohme LLC, with 400 participants enrolled, started 2020-12-16 and due to reach its primary completion in 2026-08-21. Interventions recorded: Pembrolizumab, Favezelimab/Pembrolizumab, Belzutifan, Lenvatinib, Pembrolizumab/Quavonlimab and Vibostolimab/Pembrolizumab.
Similar pages
not linked directly; found by shared links- TrialSubstudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Shares Favezelimab, Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.
- TrialA Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
- TrialPembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialSafety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
Shares Favezelimab, Lenvatinib, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
Shares Favezelimab, Merck & Co. (MSD), Pembrolizumab and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Shares Belzutifan, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
- TrialA Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD), Renal cell carcinoma and the tag pipeline.
- TrialExtension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
Shares Belzutifan, Lenvatinib, Merck & Co. (MSD) and the tag pipeline.